Global Human Plasma Market

Global Human Plasma Market: Global Size, Trends, Competitive, and Historical & Forecast Analysis, 2023-2029-

The market will expand due to the increasing demand for plasma-derived medicines, advancements in therapeutic applications, and growing aging population.

Global Human Plasma Market is valued at US$ 32.99 Billion in 2022 and it is expected to reach US$ 52.01 Billion by 2029 with a CAGR of 6.72% over the forecast period.

Scope of Global Human Plasma Market Report-

Human plasma is the liquid component of blood that remains after the red and white blood cells, platelets, and other cellular components are removed. It is a yellowish fluid rich in proteins, antibodies, enzymes, hormones, and electrolytes. The history of using human plasma dates back to the early 20^th century when it was first recognized as a valuable resource for treating various medical conditions.

The application of human plasma is diverse and encompasses several areas of healthcare. One of the primary uses is in the production of plasma-derived medicines, such as immunoglobulins, coagulation factors, and albumin, which are used to treat patients with immune deficiencies, bleeding disorders, and other medical conditions. Human plasma is also utilized in research, diagnostics, and as a source of blood products for transfusions in emergency situations.

The end-users for the human plasma market are healthcare institutions, pharmaceutical companies, research laboratories, and blood banks. These entities rely on the steady supply of human plasma to meet the demand for plasma-derived products and services.

Revenue Generation Model:

The revenue generation model for the human plasma market typically involves the collection, processing, and sale of plasma-derived products. Plasma collection centers or blood banks collect plasma from voluntary donors. The collected plasma is then processed to extract specific proteins or components, which are purified, tested, and manufactured into various therapeutic products. These products are sold to healthcare providers, distributors, and patients, generating revenue for the industry.

Supply Chain Analysis:

The supply chain model for the human plasma market involves multiple stages. It begins with donor recruitment and collection centers, where voluntary donors provide their plasma. The collected plasma is transported to specialized plasma fractionation facilities, where it undergoes processing, fractionation, and purification. The resulting plasma-derived products are then packaged, stored, and distributed to healthcare institutions, pharmacies, and other end-users.

Value Chain Analysis:

The value chain model for the human plasma market encompasses the entire process from donor recruitment to the delivery of plasma-derived products to end-users. It includes activities such as donor screening, plasma collection, processing, testing, manufacturing, quality assurance, distribution, and patient administration. Each stage adds value to the overall process, ensuring the safety, quality, and availability of plasma-derived products for medical use.

Covid-19 Impact on the Global Human Plasma Market:

The Covid-19 pandemic has had a significant impact on the human plasma market. The crisis led to disruptions in the healthcare system, including restrictions on plasma donation, reduced access to healthcare facilities, and shifts in healthcare priorities. These factors have affected the collection and supply of human plasma.

During the pandemic, the demand for plasma-derived products, such as immunoglobulins, increased due to their potential therapeutic value in treating severe Covid-19 cases. This surge in demand put additional pressure on the already strained plasma supply chain. Furthermore, the need for social distancing and safety protocols resulted in decreased donor turnout and reduced plasma collection from voluntary donors.

Additionally, the diversion of healthcare resources towards Covid-19 management and research led to a temporary slowdown in the production and distribution of plasma-derived products. Some plasma fractionation facilities had to adjust their operations or prioritize Covid-19-related activities, impacting the availability of plasma-derived medicines for non-Covid-19 conditions.

The pandemic also highlighted the importance of ensuring the safety and quality of plasma-derived products. Stringent measures were implemented to mitigate the risk of viral transmission through plasma donations and to enhance the screening and testing processes. These measures aimed to safeguard the health of both donors and recipients.

Key Players of Global Human Plasma Market Report-

The human plasma market is driven by several key players, including

• CSL Behring
• Grifols
• Octapharma
• Baxter International
• Kedrion Biopharma
• Bio Products Laboratory (BPL)
• Takeda Pharmaceutical Company
• Sanquin, LFB Group
• China Biologic Products
• Green Cross Corporation
• Shanghai RAAS Blood Products
• Biotest AG
• GC Pharma
• Interstate Blood Bank
• ADMA Biologics
• Héma-Québec
• Japan Blood Products Organization
• Indian Immunologicals Limited
• Australian Red Cross Blood Service
• and others         

Market Drivers:

Increasing Demand for Plasma-Derived Medicines: There are several factors contributing to this trend. First, the rising prevalence of immune disorders, bleeding disorders, and other medical conditions that require plasma-derived therapies is driving the need for these medicines.

Additionally, the World Federation of Hemophilia estimates that around 400,000 people worldwide have hemophilia, a bleeding disorder that often requires treatment with plasma-derived clotting factors. This indicates the demand for plasma-derived medicines among hemophilia patients alone.

And, advancements in medical diagnosis and screening are leading to improved identification and treatment of patients who can benefit from plasma-derived medicines. The expanding awareness among healthcare professionals and patients about the effectiveness of plasma-derived therapies is also fueling the demand.

Furthermore, the development of new therapeutic applications for plasma-derived products is broadening their utility and driving market growth. For example; 85% to 90% of plasma used for manufacturing medicinal products is collected as source plasma by apheresis from donors in dedicated plasma collection centers.

Aging Population: The aging population is a significant driver for the human plasma market due to the increased prevalence of age-related medical conditions that require plasma-derived therapies. As individuals age, they are more susceptible to immune disorders, clotting disorders, and other diseases where plasma-derived medicines play a crucial role.

The rising number of elderly individuals globally creates a higher demand for plasma-derived products to address their healthcare needs. The number of individuals aged 60 years and above is expected to reach 2.1 billion by 2050, accounting for approximately 21% of the global population. This demographic shift highlights the importance of plasma-based therapies in improving the quality of life and medical outcomes for the aging population, driving the growth of the human plasma market.

Market Restraints:

The high cost of plasma-derived products serves as a significant restraining factor for the human plasma market. These products involve complex and costly manufacturing processes, stringent quality control measures, and extensive research and development investments. The high production costs are often passed on to consumers, making plasma-derived therapies financially burdensome for patients and healthcare systems.

This cost barrier can limit access to these vital treatments, particularly in regions with limited healthcare resources or populations with lower affordability, impacting the market's growth potential. Efforts to address cost-effectiveness and explore alternative pricing models are crucial to overcoming this restraint and ensuring broader access to plasma-derived therapies.

Market Opportunities:

Increasing Awareness and Diagnosis of Rare Diseases: The growing awareness and improved diagnosis of rare diseases that require plasma-derived therapies present an opportunity for market growth. As more individuals are accurately diagnosed, the demand for plasma-derived products to treat these conditions is expected to increase.

Technological Advancements in Plasma Fractionation: Ongoing advancements in plasma fractionation technologies, purification methods, and manufacturing processes can improve product quality, yield, and cost-efficiency. These advancements create opportunities for more efficient production and development of new plasma-derived products.

Market Trend Analysis:

Product and Technology Development Trends:

Product and Technology Development: There is a trend towards the development of novel plasma-derived products with enhanced characteristics, such as longer half-life, improved stability, and targeted therapeutic effects. Additionally, advancements in plasma fractionation technologies, including membrane filtration and chromatography techniques, are being explored to optimize manufacturing processes.

Personalized Medicine: The concept of personalized medicine is gaining momentum in the human plasma market. Tailoring plasma-derived therapies to individual patient needs, based on factors such as genetic profiles and disease characteristics, is becoming a focus of research and development efforts.

Customer Trends:

Rising Demand for Pathogen-Reduced Plasma: With increasing concerns about the transmission of infectious agents, there is a trend towards the use of pathogen-reduced plasma products. Technologies such as solvent/detergent treatment, nanofiltration, and photochemical treatments are being employed to enhance the safety profile of plasma-derived products.

Increased Focus on Sustainability: Sustainability and environmental considerations are gaining attention in the human plasma market. Efforts are being made to reduce the environmental impact of plasma collection and processing, such as optimizing energy consumption, implementing recycling measures, and reducing waste generation.

Market Competition Nature:

The human plasma market is characterized by intense competition among key players striving to maintain and expand their market share. These companies employ various strategies to differentiate themselves, establish a competitive edge, and capture a larger portion of the market.

Past Strategies:

Product Portfolio Expansion: Companies have historically focused on expanding their product portfolios by introducing new plasma-derived therapies or improving existing products. For example; CSL Behring introduced Privigen, a new generation immunoglobulin therapy, to cater to the increasing demand for specialized immune therapies.

Research and Development Investments: Companies have heavily invested in research and development to advance the understanding of plasma-derived therapies and develop innovative products. Grifols, for instance, has dedicated significant resources to research and development, leading to the development of novel therapies and technological advancements.

Strategic Partnerships and Acquisitions: Key players in the market have pursued strategic partnerships and acquisitions to enhance their capabilities, access new markets, and expand their product offerings. Octapharma's acquisition of IBEX Technologies' Hematology Reagents Division helped strengthen its position in the plasma-derived coagulation factor market.

Future Strategies:

Market Expansion in Emerging Regions: Companies may focus on expanding their presence in emerging regions with growing healthcare infrastructure and increasing demand for plasma-derived products. They may establish partnerships or invest in infrastructure to secure a foothold in these markets.

Digitalization and Data Analytics: Companies may leverage digital technologies and data analytics to optimize plasma collection, improve manufacturing processes, and enhance supply chain management. This could lead to increased efficiency, cost savings, and improved patient outcomes.

Sustainable Practices: With a growing focus on sustainability, companies may implement environmentally friendly practices throughout the plasma collection and manufacturing processes. This could include initiatives to reduce energy consumption, minimize waste, and promote recycling.

Geography Analysis:

North America is Leading the way in the Human Plasma Market with Advanced Healthcare Systems and Innovation:

North America, comprising the United States and Canada, represents one of the largest markets for human plasma. The region boasts well-established healthcare systems, advanced infrastructure, and a high prevalence of diseases that require plasma-derived therapies. Additionally, robust regulatory frameworks ensure safety, quality, and efficacy standards for plasma-derived products.

In North America, the United States dominates the human plasma market. The country has a well-developed plasma collection infrastructure, a large donor base, and a strong presence of key market players. The US Food and Drug Administration (FDA) regulates plasma-derived products, ensuring compliance with stringent safety and quality standards.

The North American market is characterized by a high demand for plasma-derived medicines, driven by factors such as the aging population, the increasing prevalence of immune disorders, and advancements in medical technologies.

According to the U.S. Department of Health & Human Services (HHS), these diseases represent the fourth largest cause of disability among women in the United States and are the eighth leading cause of death for women between the ages of 15 and 64. The region is also at the forefront of research and development activities, focusing on product innovation, precision medicine, and personalized therapies.

Europe Holds a Prominent Position in the Global Human Plasma Market:

Europe plays a significant role in the human plasma market, both as a major consumer and producer of plasma-derived products. The region benefits from a well-established healthcare system, robust regulatory standards, and a high level of scientific and technological expertise. European countries have stringent quality and safety regulations in place to ensure the safety and efficacy of plasma-derived products, fostering trust and confidence among patients and healthcare providers.

Europe is home to several key players in the plasma industry, including CSL Behring, Grifols, Octapharma, and Biotest AG, among others. These companies have a strong presence in the European market and contribute to the availability of plasma-derived therapies for patients across the region.

For instance; in January 18^th, 2022; Octapharma announced that the indication for cutaquig, a human immunoglobulin for subcutaneous administration, has been expanded in the European Union (EU), providing more flexible treatment options to a far-wider range of patients with acquired immune deficiencies.

In terms of plasma collection, Europe has a well-developed network of plasma collection centers. Countries such as Germany, Austria, and the Czech Republic have a long history of plasma collection, with established systems for voluntary donor recruitment and collection. Plasma collection centers adhere to strict quality and safety standards, ensuring the integrity of the collected plasma.

Key Benefits of Global Human Plasma Market Report–

• Global Human Plasma Market report covers in-depth historical and forecast analysis.
• Global Human Plasma Market research report provides detailed information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, and Regional and Country Level.
• Global Human Plasma Market report helps to identify opportunities in the marketplace.
• Global Human Plasma Market report covers extensive analysis of emerging trends and competitive landscape.

 

Global Human Plasma Market Segmentation:-

By Product Type:

• Immunoglobulins
• Coagulation Factors
• Albumin
• Protease Inhibitors
• Other Plasma-Derived Products

By Source:

• Fresh Frozen Plasma (FFP)
• Recovered Plasma
• Source Plasma

By Mode of Delivery:

• Infusion Solutions
• Gels
• Sprays
• Biomedical Sealants

By Application:

• Hematology
• Immunology
• Neurology
• Critical Care
• Pulmonology
• Rheumatology
• Others

By End-User:

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Research Institutes
• Others

By Regional & Country Level:

• North America
  • S.
  • Canada
• Europe
  • K.
  • France
  • Germany
  • Italy
• Asia Pacific
  • China
  • Japan
  • India
  • Southeast Asia
• Latin America
  • Brazil
  • Mexico
• Middle East and Africa
  • GCC
  • Africa
  • Rest of Middle East and Africa